Anyone? Anyone?

Posted Thursday, April 26, 2007 @ 01:04 AM
Anyone? Anyone out there for me?
No one is responding to my post yesterday here in Endogyn!
I NEED a response to it from ANYONE! Sandy, we can talk about dogs or cows, just reply to my post or it will appear that I have no friends or followers!
respond to my post! I NEED a fix!
Karen, Helen, Connie, Jan, anyone! I am sinking in my own stink!
Karen, you can promote your book on Endogyn again, Connie can advertise her "beer pong" under age drinking parties, Jan, well, Jan you can just praise me, and Helen, you can have the Endogyn web site, all of it, it is yours! Just reply, anyone!

Okay, look, you can all have a FREE surgery by me in my new facility near, no, I mean, IN Fuldi! Yeah, that's it, FREE surgery with me, the best and most brilliant surgeon in the world, you ALL know this, remember?
It's ME, Kru, your wining and dining buddy!
Hey, come on guys, ally, all come free, come on out where I can see you, just post!

If you don't post, I will start telling our secrets on my message board! Do you want that, huh!!? So There! I am watching to see who my REAL followers are! I demand that someone reply to my post! I order it!
Daniel Kruschinski, MD EndoGyn.com, Adhesions.de, Hysterectomy.de, Fibroids.de, Endometriosis.de, Lift-laparoscopy.com © by EndoGyn Ltd.

Posted Wednesday, April 25, 2007 @ 01:04 AM
Hello and greatings from Nepal from the Internationl OB/GYN conference in Kathmandu, where I ahve a lecture about Lift laparoscopy for two hours and will be demonstrating the technique to around 300 gynecologic surgeons from Nepal.

Daniel Kruschinski, MD EndoGyn.com, Adhesions.de, Hysterectomy.de, Fibroids.de, Endometriosis.de, Lift-laparoscopy.com © by EndoGyn Ltd.



Second part of one of Kruschinski's many address's and hideouts!
(This is more for Kruschinski's benefit then anything else. He seems to like games, so IHRT is accommodating that.)
Falkenhausenweg 54

Abdolift, adhesions, Con Man, Crime, Dr Kruschinski, Dr.Daniel Kruschnski, Endogyn, Hon Code violations, ISGE.org, Lift Laparoscopy, SprayGel, Nepal, International Ob/GYN, HOMBERG,

Adhesions Medical Headlines ARDvark Blog

Chronic Family Turmoil And Other Problems Cause Physical Changes

Food Preparation May Play A Bigger Role In Chronic Disease Than Was Previously Thought

New Hope For Antibiotic Resistance

Green Tea May Help Prevent Autoimmune Diseases

Juries More Likely To Favor Defendants In Malpractice Lawsuits, Study Finds

Insured U.S. Women More Likely To Forgo Needed Care Than Men, According To Study

Women And Health Coverage: The Affordability Gap

Gall Bladder Removed Vaginally Using Endoscope With Minimal External Incisions

FDA Approval Of Wyeth Menopause Treatment Pristiq Delayed

American Pain Society Announces Recipients Of Clinical Centers Of Excellence In Pain Management Awards

Innocoll Announces Outcome Of FDA Meeting To Commence Phase 3 Development Of Its CollaRx(R) GENTAMICIN SURGICAL IMPLANT For Surgical Infections

Wyeth Receives Approvable Letter From FDA For Bazedoxifene For The Prevention Of Postmenopausal Osteoporosis

Pain Management Conference Augusta, GA May 18-19, 2007 Attracts Top Pain Experts

Inflammatory Bowel Disease Linked To Nerve Damage

Many Companies Sent Warning Letters About Marketing Alternative HRT Still Selling Products, FTC Official Says

Decline In Breast Cancer Incidence Sustained In 2004, Study Says; Drop Linked To Reduction In HRT Use

Anal Fissures Treatment

Adhesions Medical Headlines ARDvark Blog

New York Times Examines Debate Over Experimental Oral Contraceptives That Eliminate Monthly Menstrual Periods

Did Drug Reps Encourage Doctors To Prescribe Gabapentin For Non-approved Uses?

GP Surgeries With Specialist Nurses Can Help Save Lives New Research

Use Caution When Treating Seasonal Allergies

Company's Adaptive Scanning Optical Microscope Eliminates Traditional Trade-Off Between Magnification, Field Of View

Public Citizen Ranks State Medicaid Programs, Finds Wide Variation In Eligibility, Benefits, Performance

Medicare Fraud Costs Billions Of Dollars Each Year, CMS Officials Testify

Sen. Kennedy Circulates Generic Biotech Drugs Draft Bill

HRT Increases Incidence And Deaths From Ovarian Cancer

BioXell S.p.A. Shareholders unanimously approve all Board of Directors' proposals at Annual General Meeting

BioXell S.p.A. Shareholders unanimously approve all Board of Directors' proposals at Annual General Meeting
Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement.
Milan, Italy, April 24, 2007 - Shareholders of BioXell S.p.A. (SWX:BXLN) unanimously approved all items proposed by the Board ofDirectors at today's Annual General Meeting in Zurich.
These included: * the approval of the 2006 statutory financial statements of BioXell S.p.A. * the appointment of Dr. Werner Lanthaler as member of the Board of Directors * the re-election of KPMG S.p.A. as External Auditors of the company * the increase of the authorized capital reserved to the beneficiaries of the company's stock Option plan * the increase of the authorized capital reserved for strategic investments up to a maximum of 50% of the existing share capital, thus granting the company the flexibility to actively pursue strategic investments and in-licensing of complementary therapeutics within its areas of focus.The Annual General Meeting was attended by Shareholders whorepresented 54.87% of the total share capital of the Company.Dr. Thomas Szucs, Chairman of BioXell, commented, "It's an excitingtime to be a Shareholder and participate in the BioXell story, as theCompany enters a new phase in its maturation, with the goal ofbecoming a fully integrated biopharmaceutical company and a keyplayer in the management of urological disorders. BioXell reached keymilestones in 2006 in the development of Elocalcitol for two majorurological disorders, Benign Prostatic Hyperplasia and OveractiveBladder, either of which represents a potential blockbuster marketfor the Company's lead compound. Furthermore, Elocalcitol will beentering clinical trials for a third indication, Male Infertility,later this year, while a new compound acquired from Roche will beadvanced into Phase II trials for Post-Surgical Adhesions in 2008."About BioXellBioXell (SWX: BXLN) is a biopharmaceutical company focused on thediscovery and development of drugs that exploit novel mechanisms ofaction to treat important urological, inflammatory, and related disorders with significant unmet medical needs. The Company wasfounded in 2002 as a spin-out from Roche. BioXell's strategic goal isto become a fully integrated pharmaceutical company by maximizing thecommercial potential of its product Portfolio and leveraging existingplatforms into profitable partnerships.BioXell's lead compound, Elocalcitol, derived from its proprietaryVD3 (Vitamin D3) technology platform, is in Phase II clinical trialsfor Benign Prostatic Hyperplasia (BPH) and Overactive Bladder (OAB),with a third Phase II trial for Male Infertility scheduled for 2007.In addition, the Company has several follow-on programs based on bothVD3 and other technological platforms. BXL746 is to enter Phase IItrials for Post-Surgical Adhesions in 2008. In 2006, BioXellin-licensed from Lay Line Genomics S.p.A. a novel anti-TrkAmonoclonal antibody, MNAC13, which represents an innovative newapproach to the treatment of pain. BioXell also has an exclusivepartnership with Merck & Co., Inc. since 2005 for the development ofits TREM platform, with TREM-1 in development for the treatment ofseptic shock.In June 2006, BioXell listed its shares on the main segment of theSWX Swiss Exchange. BioXell currently employs 60 people and has sitesin Milan, Italy and Nutley, NJ, USA. More information on BioXell can be found at: http://www.bioxell.com

Adhesions Medical Headlines ARDvark Blog

Women More Likely Than Men To Go Without Health Care, USA
Written by Christian Nordqvist
With 38% of American women finding medical bills a serious struggle, compared to 29% of men, a new study released by the Commonwealth Fund reveals that women are much more likely to go without needed healthcare than men, because they cannot afford it...[read article]

Clinical Trials: Is The Gold Standard Good Enough?

Placebo Effect In The Pharmacologic Treatment Of Patients With Lower Urinary Tract Symptoms

Difficult Births In Obese Women Due To Uterus Failure

Wyeth Comments On Report On Hormone Therapy And Ovarian Cancer from The Million Women Study In The Lancet

Pregnancy Hormone Key To Repairing Nerve Cell Damage - MS Society Of Canada

News Tips From The Journal Of Neuroscience

Screening For Abdominal Aortic Aneurysms Saves Men's Lives

Radiosurgery An Effective Noninvasive Treatment Option For Trigeminal Neuralgia-Related Pain

Replicating Stress-Induced Analgesia May Hold Promise For Patients With Intractable Pain

In Uncomplicated Open Cholecystectomy Drains Should Not Be Used

No-Scalpel Vasectomies By Skilled Surgeons May Speed Recovery

Vaginal Dysplasia

Vaginal Dysplasia CME
News Author: Will Boggs, MDCME Author: Désirée Lie, MD, MSEd DisclosuresRelease Date: April 20, 2007; Valid for credit through April 20, 2008
Credits Available
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™ for physicians;Family Physicians - up to 0.25 AAFP Prescribed credit(s) for physicians
April 20, 2007 — Ultrasonic surgical aspiration offers significant advantages over laser ablation for vulvar and vaginal intraepithelial neoplasia, according to a report in the April issue of Obstetrics & Gynecology.
"I favor the USA (ultrasonic surgical aspiration) based on the pain data and the cosmetic result," Dr. Vivian E. von Gruenigen from University Hospitals Case Medical Center, Cleveland, Ohio, told Reuters Health. "If I as a woman had vulvar dysplasia, I would request the USA."
Dr. von Gruenigen and colleagues compared postoperative adverse effects, pain, and recurrence rates between laser ablation and ultrasound surgical aspiration for 96 women with vulvar intraepithelial neoplasia or vaginal intraepithelial neoplasia.
Laser surgery was performed with a carbon dioxide laser, with tissue destruction to a depth of 1 - 3 mm depending on location. With ultrasonic surgical aspiration, the authors note, "the handheld tool vibrates and contains separate irrigation and suction channels. Lesions are removed to the reticular layer of the dermis."
Women treated with ultrasound surgical aspiration experienced less pain than women treated with laser. Visual analog scale scores were 20.7 compared with 35.1 (P = 0.032), the authors report. In addition, women with vulvar dysplasia had less scarring after ultrasonic surgical aspiration than after laser ablation.
Recurrence rates during the year after surgery were similar with ultrasonic surgical aspiration (24.4%) and laser (25.5%), the report indicates, and recurrence rates were higher for vulvar procedures than for vaginal procedures, regardless of treatment.
Recurrence rates did not differ for patients treated for new disease compared with recurrent disease, the researchers note. In fact, on multiple logistic regression, age was the only factor significantly associated with recurrence.
Both treatments had similar adverse effects, according to the investigators, including minor genital complaints of infection, dysuria, burning, adhesions, and discharge.
Read More

Adhesions Medical Headlines Ardvark Blog

Studies Confirm Long-term Protection Against Precancerous Cervical Lesions With Vaccines Against Human Papilloma Viruses (HPV)
Written by Susan Mayor
Follow-up studies of two vaccines against HPV causing cervical cancer have shown long-term protection against precancerous lesions, according to results reported at the 2007 Annual Meeting of the American Association for Cancer Research (14-18 April, 2007; Los Angeles, USA)...[read article]

CMS Announces Proposed Rule That Would Adjust Medicare Inpatient Hospital Payments Based On Severity Of Beneficiary's Illness

New Reflux Guidelines Released - American College Of Gastroenterology Offers Esophageal Reflux Testing Recommendations

Early Stage Pancreatic Cancer Expresses Antigen Targeted By Immunomedics' PAM4 Antibody

The U.S. Food And Drug Administration Approves New Actonel Dose To Treat And Prevent Postmenopausal Osteoporosis

New One-Year Pharmacoeconomic Study Shows Avonex® Is Cost-Effective Relative To Other Interferon Therapies For Multiple Sclerosis

Cetuximab Improves Overall Survival In Advanced Colorectal Cancer

Commission Questions Army Disability Evaluation System

Tens Of Thousands Of Beneficiaries Await Medicare Part B Refunds

Online Tool Presents Hydration Guidelines For Consumers - IBWA Hydration Calculator Provides Helpful Information

Better Information For Hospitals In The Fight Against C Difficile, UK

FDA Panel Members Considering COX-2 Inhibitor Have Financial Ties To Industry

Malpractice Study -- Juries Sympathize More With Doctors

Several States Consider Legislation That Would Make Physician Apologies Inadmissible As Evidence Of Guilt In Medical Malpractice Lawsuits

Clues To Ovarian Cancer's Deadly Secrets

Yeast Infections Causes And Symptoms

How Do The Rules Of Immunity Change During Chronic Infections?

3 Proteins May Play Important Role In Nerve-Cell Repair

Farewell To 'Collateral Damage' In Surgery

Treating fibroids

The treatment of fibroids depends on several factors, including whether the patient intends to have more children.
THE DOCTOR SAYS by DR MILTON LUM
THE symptoms, complications, diagnosis and assessment of fibroids were discussed a fortnight ago.
This article addresses the treatment of fibroids, which depends on the size of the growths, symptoms, the age of the woman, whether or not she plans to have more children and her preferences.
Regular assessment
Fibroids which are small and do not produce symptoms usually do not require treatment, especially if one is nearing menopause (average age 50).
If the fibroids are small and there is no pain, pressure symptoms or excessive menstrual bleeding, regular assessments are all that is needed.
The objective of these examinations is to determine if there is significant change in the size of the fibroids.
This is particularly necessary if one is planning to get pregnant, as the fibroids can grow and affect the pregnancy, or if one is approaching menopause, when the fibroids usually shrink in size.
It is important to keep the appointments with the doctor for these regular check-ups.
There is no need to limit any regular activities, including sexual intercourse, unless the fibroids cause pain during intercourse, in which case the doctor should be consulted.
Indications for treatment
The presence of certain signs and symptoms may indicate the need for treatment. They include heavy or painful periods; pelvic pain; bleeding between periods; rapid increase in the size of the fibroids; uncertainty about the nature of the growth (i.e. fibroid or another tumour, e.g. an ovarian tumour); infertility; or pressure symptoms (e.g. urinary or bowel symptoms).
Surgical treatment
Surgical methods of treatment are effective in treating fibroids.
The fibroids may be removed by myomectomy or hysterectomy. The choice depends on the patient’s preferences and medical advice.
a. Myomectomy is a procedure in which only the fibroids are removed, leaving the uterus in place. It is usually performed when there is desire for a future pregnancy or when a woman wants to retain her uterus.
Fibroids may recur after a myomectomy. If they do, more surgery is needed.
Sometimes when there is excessive scar formation following a myomectomy, fertility may be affected, especially if the scar tissue affects the ovaries and fallopian tubes.
The size and location of the fibroids as well as any other pelvic condition that may be present will determine the appropriate surgical approach.
Small fibroids are removed through less invasive hysteroscopy or laparoscopy procedures. Large, multiple or inaccessible fibroids and the presence of other pelvic conditions and/or adhesions usually require a laparotomy.
b. Hysterectomy is the surgical removal of the uterus, and is an effective cure for fibroids. It may be considered when there is persistent pain or abnormal bleeding; the fibroids are large; other methods of treatment are not possible; children are not desired; or it is the patient’s decision.
The hysterectomy can be carried out through the vaginal route or through a laparotomy.
After a total hysterectomy, contraception is no longer needed and the risks of cervical and endometrial cancer are removed.
The ovaries may or may not be removed at the time of hysterectomy, depending on the patient’s age, and whether there are any co-existing conditions in the ovaries. Again, the patient has to decide.
Uterine artery embolisation (UAE)
In this recently introduced procedure, particles are inserted into the uterine arteries, through a narrow tube inserted in the groin, to shrink the fibroids by blocking off their blood supply.
The procedure is done by an interventional radiologist after the patient’s suitability for such treatment has been assessed by a specialist team, which includes a gynaecologist. It must be emphasised that there are very few such teams in the country.
There is a need for more information about how well UAE works, how long it works, and how it affects a woman’s ability to get pregnant. In short, the jury is still out on this procedure.
Medical treatment
Medicines may be prescribed to treat the problems caused by fibroids, or to temporarily reduce the size of the fibroids.
Anaemia can be corrected with oral iron supplements.
Infection can be treated with antibiotics.
Antiprostaglandins or cyclo-oxygenase enzyme (COX) inhibitors are taken only during menstruation and are suitable for women trying to conceive or who have associated period pains.
GnRH analogues are used to temporarily reduce the size of large fibroids and to control bleeding, in preparation for surgery.
They act by stopping the hormones from the brain which control the production of ovarian hormones. Oestrogen levels decrease considerably, leading to a significant reduction in the size of the fibroids.
However, when treatment is discontinued, the fibroids will usually – within three to six months – return to their pre-treatment size.
Emotional aspects
The feelings of women with fibroids vary. Some feel that something is not right with their femininity as their reproductive organs are affected.
It is important to remember that there are many aspects to femininity and it is not confined to one part of the body.
The woman who has had a miscarriage may feel angry, guilty or anxious about future pregnancies. If she has to face the possibility of losing her uterus, especially when future pregnancy is desired, there may be anger and sadness.
It is important that you discuss your feelings and preferences are discussed with the doctor who will assist you in handling them and advise you on the treatment options.
Conclusions
Fibroids are common non-cancerous growths of the uterus. They may be small and cause no symptoms, thereby requiring no treatment.
When they are large or there are pressure symptoms or pain, or changes in menstruation, medical attention is necessary.
If you have fibroids now, or in the past, you should consult your doctor regularly for assessment.
There is no way to determine any abnormality until the doctor has examined you. Once the cause is found, you can be treated effectively.
Dr Milton Lum is chairperson of the Commonwealth Medical Trust. This article is not intended to replace, dictate or define evaluation by a qualified doctor. The views expressed do not represent that of any organisation the writer is associated with.
Source

U-M’s World Robotic Gyn Symposium to feature three live robot-assisted telesurgeries

NN ARBOR, Mich. — Three live robot-assisted telesurgeries are highlights at the 2007 World Robotic Gyn Symposium, April 13-14 at Palmer Commons on the U-M campus.

The live telesurgeries will take place at teaching hospitals in three separate locations – New Jersey, North Carolina and Arizona – and will be viewed at the symposium as they occur. The procedures highlight an innovative use of technology in medical care: a surgical robot that assists surgeons as they perform minimally invasive procedures.

Gynecologic surgeons from as far away as Singapore and Italy are in town for the symposium, which is hosted by the U-M Department of Obstetrics and Gynecology. Arnold P. Advincula, M.D., FACOG, FACS, will be the course director, and other leading faculty in the field also will participate. Advincula is associate professor of obstetrics and gynecology and director of the department’s Minimally Invasive Surgery Program & Fellowship.

Advincula, who is recognized worldwide as an expert in the use of the da Vinci Surgical System, says the robot assists with extremely precise movements of the surgeon’s hands, and provides imaging that helps the surgical team navigate a minimally invasive procedure.

“With a robot-assisted, minimally invasive approach, we are able to more clearly discern the tissue planes during surgeries such as hysterectomies,” says Advincula. “This is especially helpful when the patient’s condition is complicated by tissue adhesions or endometriosis,” a condition in which the lining of the uterus is found outside the uterus.

Advincula notes that one of the advantages of a robot-assisted, minimally invasive hysterectomy is that it causes less pain to the body, smaller incisions, and often a quicker recovery time than traditional hysterectomies with an open incision. Another option for women is a minimally invasive (or laparoscopic) hysterectomy that is not assisted by a surgical robot.

The course is designed for gynecologic surgeons already performing minimally invasive surgery, who have either incorporated or plan to incorporate robotics in their practice. The course will review the current applications of robot-assisted laparoscopy in gynecology with an emphasis on the daVinci Surgical System. More information is available at the here.
Written by: Mary Beth Reilly
Source:
www.med.umich.edu/opm/newspage/2007/RobotGyn.htm

Adhesions Medical Headlines from ARDvark Blog

Unexpected Findings Offer Insight Into T Cell Development, Possible Therapies For Immune Disorders

Bush Administration Opposition To SCHIP Expansion Criticized

Uninsured Minnesotans To Continue Receiving Discount Hospital Charges

Maine Gov. Baldacci Releases Series Of Proposals To Expand Health Coverage

New Drug Shows Promise For Treating Epileptic Seizures, Bipolar Disorder And Neuropathic Pain

Online 'Pillbox' To Remind People To Take Medications

Business Executives Call For U.S. Health System Change As Costs Continue To Increase

Follistim® Introduced In Japan In A Further Indication For The Treatment Of Infertility

Adhesions Clinical Trials from clinical trials.gov

23 studies were found.
1.
Recruiting
DuraGen Plus® Adhesion Barrier for Use in Spinal SurgeryConditions: Spinal Injuries; Adhesions
2.
Recruiting
Pregabalin for Abdominal Pain From AdhesionsConditions: Abdominal Pain; Surgical Adhesions
3.
Recruiting
Collagenase in the Treatment of Zone II Flexor Tendon Adhesions in the HandCondition: Hand Zone II Flexor Tendon Adhesions
4.
Recruiting
Pediatric Multicenter Study of REPEL-CVCondition: Adhesions
5.
Recruiting
Use of G-CSF to Obtain Blood Cell PrecursorsConditions: Chronic Granulomatous Disease; Healthy; Immunologic Disease; Leukocyte Adhesion Deficiency Syndrome; Severe Combined Immunodeficiency
6.
Recruiting
Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis VulgarisConditions: Psoriasis; Psoriasis Vulgaris
7.
Recruiting
Evaluation of Patients With Immune Function AbnormalitiesCondition: Immune System Diseases
8.
Recruiting
Effect of Exercise and Diet on Inflammation in Hypertensive IndividualsCondition: Hypertension
9.
Recruiting
Irbesartan/Hydrochlorothiazide National Taiwan University Hospital ListingCondition: Hypertension
10.
Recruiting
Combination Chemotherapy After Surgery in Treating Patients With Stage I, Stage II, or Stage III Breast CancerCondition: Breast Cancer
11.
Recruiting
Familial Mediterranean Fever and Related Disorders: Genetics and Disease CharacteristicsCondition: Periodic Disease
12.
Recruiting
Collagenase in the Treatment of Adhesive Capsulitis (Frozen Shoulder)Conditions: Adhesive Capsulitis; Frozen Shoulder
13.
Recruiting
Study of the Composition of Dental PlaqueConditions: Dental Caries; Dental Plaque; Periodontal Disease
14.
Recruiting
Genetic Factors in Age-Related Macular DegenerationCondition: Macular Degeneration
15.
Recruiting
Efalizumab to Treat UveitisConditions: Uveitis; Intraocular Inflammatory Diseases
16.
Recruiting
Raptiva to Treat Sjogren's SyndromeCondition: Sjogren's Syndrome
17.
Not yet recruiting
Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel ObstructionCondition: Small Bowel Obstruction
18.
Recruiting
A Safety Study of Two Intratumour Doses of Coxsackievirus Type A21 in Melanoma Patients.Condition: Stage IV Melanoma
19.
Not yet recruiting
Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot StudyCondition: Coronary Artery Disease
20.
Recruiting
Study on the Efficacy and Mechanism of Cardiac Rehabilitation for Stem Cell Mobilization and Heart Failure ImprovementCondition: Myocardial Infarction
21.
Recruiting
Detection and Characterization of Host Defense DefectsConditions: Immunologic Deficiency Syndrome; Infection
22.
Recruiting
Allogeneic and Matched Unrelated Donor Stem Cell Transplantation for Congenital Immunodeficiencies: Busulfan-Based Conditioning With Campath- 1H, Radiation, and SirolimusConditions: MUD Transplant; AlloPBSC; Congenital Immunodeficiencies; HLA Matched Transplant; BMT
23.
Not yet recruiting
Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin.Conditions: Diabetes Mellitus; Hypertension

http://clinicaltrials.gov/ct/search?term=adhesions

Adehsions Medical Headlines ARDvark Blog

HSAs Often More Expensive For Women, Study Says
Women are more likely to pay more than men for health care when enrolled in high-deductible health plans, which have low premiums and in some cases include health savings accounts and health reimbursement arrangements, according to a study published in the April issue of the Jo.....[read article]

Sen. Obama Seeking Public Input, Consensus As He Develops His Health Care Proposal

Laparoscopic Inguinal Herniotomy In Bladder Exstrophy: A New Solution To An Old Problem?

Does Percutaneous Nephrolithotomy In Children Cause Significant Renal Scarring?

Ibuprofen Puts High Risk Cardiac Patients At Risk--Drug Interaction May Cause Heart Attacks

Stress Increases Inflammation In Pregnancy, Putting Women At Risk

Highlights From The April Journal Of Neuroscience

HIPAA Allows Police Access To Alleged Crime Victims In Hospitals

Asherman's Syndrome

Also called "uterine synechiae", presents a condition characterized by the presence of scars within the uterine cavity.

Features
The cavity of the uterus is lined by the endometrium. This lining can be traumatized, typically after a dilation and curettage (D&C) done after a miscarriage, abortion, or delivery, and then develops intrauterine scars which can obliterate the cavity to a varying degree. In the extreme, the whole cavity has been scarred and occluded. Even with relatively few scars, the endometrium may fail to respond to estrogens and rests. The patient experiences secondary amenorrhea and becomes infertile. An artificial form of Asherman's syndrome can be surgically induced by uterine ablation in women with uterine bleeding problems, in lieu of hysterectomy.

Diagnosis
The history of a pregnancy event followed by a D&C leading to secondary amenorrhea is typical. Imaging by gynecologic ultrasonography or hysterosalpingography will reveal the extent of the scar formation. Hormone studies show normal levels consistent with reproductive function. There are ways to lower the risk of developing Asherman's after a D&C, such as hormone therapy to cause sloughing off of the uterine lining.
Ultrasound is not a reliable method of diagnosing Asherman's Syndrome. Options include HSG (hysterosalpingography) or SHG (sonohysterography). Hysteroscopy is the most reliable. The website at http://www.ashermans.org gives more detail.

Treatment
Operative hysteroscopy is used for visual inspection of the uterine cavity and dissection of scar tissue.

Prognosis
The extent of scar formation is critical. Small scars can usually be treated with success. Extensive obliteration of the uterine cavity may require several surgical interventions or even be uncorrectable. Patients who carry a pregnancy after correction of Asherman's syndrome may have an increased risk of having a placenta that invades the uterus more deeply, leading to complications in placental separation after delivery.

History
It is also known as Fritsch syndrome, or Fritsch-Asherman syndrome per the individuals who described it, Heinrich Fritsch and Joseph G. Asherman.
Ashermans.org
NIH/Medline plus
iVillage

Source

Fast Facts for Your Health: Pelvic Adhesions

Author: National Women's Health Resource CenterPublished by: National Women's Health Resource Center, Inc., April 2007Pelvic adhesions are gynecologic surgery side effect that can lead to infertility, pain and more surgeries. But, your surgeon can reduce your risks for developing adhesions following surgery in a number of ways including using adhesion prevention barriers. Fast Facts for Your Health: Pelvic Adhesions explains what you should discuss with your health care team before your surgery.
This publication was produced with support from Ethicon Women's Health & Urology, a division of ETHICON, Inc.
Price: $0.00 - free download
Source

Severe Complications Of Circumcision: An Analysis Of 48 Cases

UroToday.com- A study by Ceylan, et al from Turkey evaluated their experience in 48 cases of severe complications of circumcisions. Their patient's ages ranged from 5 months to 24 years with the mean age of 14 years. These circumcisions were performed at various centers or during religious ceremonies in environments other than health facilities.The group found that the most commonly observed complication was preputio-glandular fusion that was seen in 25 cases (52%.). The other complications were as follows: meatal stenosis in 11 (23%); urethral fistula in 5 (10.4%); partial glandular amputation in 4 (8%); and a distal urethral fistula in 3 (6%). Lysis of adhesions and revisions were performed in all cases of preputio-glandular fusion. The patients with meatal stenosis underwent meatotomies. The urethral fistula cases were repaired by simple closure and not a hypospadias type repair. Partial glans amputations were patched only with buccal mucosa. There was one patient with a completely open distal urethra that appeared to be more of a megameatus in my interpretation that was repaired by a Mathieu in a tabularized incised plate urethroplasty type technique.The group concluded that circumcisions are routine but they may be associated with serious complications. The group felt that experience played a major role and that when circumcisions are performed, they should be done by educated experience personnel.Kadir Ceylan, Koseoglu Burhan, Yuksel Yilmaz, Saban Can, Alpaslan Kus, and Gunes Mustafa.Journal of Pediatric Urology 3(1): 32-35, February 2007Reviewed by UroToday.com Contributing Editor Pasquale Casale, MD
Source

BioXell Reports 2006 Financial Results and Highlights For the Year

MILAN, Italy, April 10, 2007 - BioXell S.p.A.
(SWX: BXLN) today reported its financial results for the full year 2006. The year was marked by a successful IPO on the SWX Swiss Exchange in June, raising a total of € 40 million, as well as a private financing round in March which raised an additional € 10.5 million. The Company ended the year 2006 with solid cash reserves of € 71 million. Lead compound Elocalcitol reached Phase II milestones in two key urological indications, with trials in a third indication scheduled for 2007. A second clinical stage asset acquired from Roche, BXL 746, is to be advanced into Phase II trials next year.
BioXell's healthy financial position and a modest cash burn rate estimated at € 17 million for 2007 put the Company in a strong position to advance the development of its clinical and preclinical phase assets while continuing to pursue strategic partnerships, in-licensing and M&A activities.
Francesco Sinigaglia, CEO of BioXell, commented, "2006 was an important year for BioXell during which we made substantial progress in the development of our pipeline. We reached key Phase II milestones for Elocalcitol, acquired new clinical and preclinical assets, and obtained scientific results that will lead to clinical trials in two new indications. With a successful IPO and additional private financing, combined with a disciplined cash burn rate, we ended the year on very solid financial footing. We are well situated to drive forward our clinical programs, maximize the potential of Elocalcitol and explore other opportunities to expand our pipeline."
BioXell also announced that it has now been added to the SWX Swiss Exchange's SXI LIFE SCIENCES and SXI Bio+Medtech indices, as of April 2, 2007. The full 2006 Annual Report is available and can be downloaded from the BioXell website at www.bioxell.com. Hardcopies will go out by regular mail at the end of next week.
R&D Highlights 2006 was a significant year for BioXell as the company delivered progress on multiple fronts, advanced its in-house programs, enriched its overall pipeline, and increased shareholder value.
* Elocalcitol reaches Phase II milestones in two key urological indications The clinical development of Elocalcitol in two major urological indications is proceeding on schedule. The completion in May 2006 of the Phase IIa trial of Elocalcitol in Overactive Bladder was a decisive milestone. The results indicated that BioXell's lead compound may have comparable efficacy to the "gold standard" anti-cholinergics in this indication, while avoiding the side effects typically associated with this class of products. In the first half of 2007 the Company will continue with a sophisticated "urodynamic" Phase IIb study, with results due in 2008. Meanwhile, in December 2006 enrolment was completed in the Phase IIb trial of Elocalcitol in Benign Prostatic Hyperplasia - the largest study ever conducted using MRI (Magnetic Resonance Imaging) to measure prostate volume. Results will be available in the second half of 2007. Success in either of these large indications will confirm Elocalcitol's blockbuster potential.
* Elocalcitol to enter clinical trials for Male Infertility A trial of Elocalcitol in Chronic Prostatitis that ended in 2006 showed no effect on the primary endpoint of pain reduction, but BioXell's scientists observed a significant reduction in the semen levels of IL-8, a marker of inflammation correlated with poor semen quality. A Phase II trial to study the effect of Elocalcitol on semen parameters is scheduled for the second half of 2007, potentially opening up a whole new therapeutic indication for this remarkable compound.
* BXL746 to enter clinical trials for Post-Surgical Adhesions BioXell acquired from Roche a second clinical stage asset, BXL746, which will be advanced into Phase II trials next year for Post-Surgical Adhesions. Following observations made while profiling BXL746 in a number of inflammatory conditions, BioXell's scientists confirmed the compound's efficacy in reducing adhesion formation in animals. Adhesions are an extremely frequent, unpleasant and painful complication of surgery, and the medical need for avoiding them is substantial.
* Preclinical pipeline Two other preclinical projects are moving along nicely. MNAC13, a fully humanized antibody acquired from Lay Line Genomics in late 2005, represents an exciting and innovative new approach to treating chronic and acute pain that may avoid the drawbacks of current treatments. It is currently being further characterized pharmacologically in-house in anticipation of its advancement into clinical trials. Meanwhile, BioXell's collaboration on the TREM platform with Merck & Co. is continuing on schedule, focusing on TREM-1 as a means of preventing Sepsis - a massive infection that is the primary cause of hospital deaths in emergency care units.
2006 Financial Highlights * € 40 million raised through a listing on the SWX Swiss Exchange in June * € 10.5 million in equity raised in a private financing round in March * Cash reserves of € 71 million at year-end * Cash burn of € 14. million for 2006 (vs € 7.5 million in 2005), reflecting an increase in R&D activities to € 12.4 million (vs € 9.4 million in 2005) * Net loss of € 13.8 million
Revenues Total revenues in 2006 amounted to € 2.5 million. BioXell currently derives revenues from its collaboration with Merck & Co., which accounted for € 1.7 million in 2006, and from research grants.
Operating expenses Total operating expenses in 2006 were € 17.9 million versus € 13.6 million in 2005, an increase of 32%. BioXell is channelling most of its operating expenses (69%) into the development of its R&D pipeline.
Total R&D expenses amounted to € 12.4 million versus € 9.4 million in 2005, an increase of 32% largely due to the increase in clinical trial costs for Elocalcitol - which completed enrolment of a 500+ patient trial in Italy and Germany - as well as the costs associated with the acquisition and development of MNAC13 and BXL746.
General and Administrative expenses were € 5.5 million, representing 31% of total operating expenses. These included mainly General Management, Business Development, Information Technology and Communications.
Net Loss The Company recorded a total net loss of € 13.8 million in 2006.
Balance sheet As a result of the IPO, and considering the net loss for the year, total shareholders' equity grew, as of December 31, 2006, to € 66.2 million versus € 33.9 million in the previous year, an increase of 95%. The Company ended the fiscal year with € 71 million in cash and investment securities, and maintained € 3.5 million in debt, a result of public financing on favourable terms.
Financial outlook BioXell expects a monthly cash burn rate of € 1.4 million in 2007 - in the vicinity of € 17 million for the year - as it continues to expand its R&D activities. In particular, 2007 will see the completion of a Phase IIb trial of Elocalcitol in BPH, the start of a Phase IIb trial of Elocalcitol in OAB, and the start of a Phase IIa trial of Elocalcitol in Male Infertility. The Company is exercising strong financial discipline as it makes maximum use of its resources to fund the advancement of its pipeline.
Additional information is available on the BioXell website at www.bioxell.com.
About BioXell BioXell (SWX: BXLN) is a biopharmaceutical company focused on the discovery and development of drugs that exploit novel mechanisms of action to treat important urological, inflammatory, and related disorders with significant unmet medical needs. The Company was founded in 2002 as a spin-out from Roche. BioXell's strategic goal is to become a fully integrated pharmaceutical company by maximizing the commercial potential of its product portfolio and leveraging existing platforms into profitable partnerships.
BioXell's lead compound, Elocalcitol, derived from its proprietary VD3 (Vitamin D3) technology platform, is in Phase II clinical trials for Benign Prostatic Hyperplasia (BPH) and Overactive Bladder (OAB), with a third Phase II trial for Male Infertility scheduled for 2007. In addition, the Company has several follow-on programs based on both VD3 and other technological platforms. BXL746 is to enter Phase II trials for Post-Surgical Adhesions in 2008. In late 2005, BioXell in-licensed from Lay Line Genomics S.p.A. a novel anti-TrkA monoclonal antibody, MNAC13, which represents an innovative new approach to the treatment of pain. BioXell also has an exclusive partnership with Merck & Co., Inc. since 2005 for the development of its TREM platform, with TREM-1 in development for the treatment of septic shock.
In June 2006, BioXell listed its shares on the main segment of the SWX Swiss Exchange. BioXell currently employs 60 people and has sites in Milan, Italy and Nutley, NJ, USA. More information on BioXell can be found at: http://www.bioxell.com
Please see the attachment for the complete press release. For further information, please contact:
BioXell S.p.A. Rochat & Partners Alvise Sagramoso/Angela Evans Christophe Lamps/Jonathan Leighton Tel: +39 (0)2 210 49 51 Tel: +41 22 718 37 46 Fax: +39 (0)2 210 49 529 Fax: +41 22 786 54 58 alvise.sagramoso@bioxell.com clamps@rochat-pr.ch angela.evans@bioxell.com jleighton@rochat-pr.ch
Source

Special Prayer Request

Asking for special prayers for a surgery that happened this past week in Ohio.

Please take a moment.

Adhesions Medical Headlines ARDvark Blog

Cocoa But Not Tea Linked To Blood Pressure Reduction
Written by Catharine Paddock
A German study suggests there is evidence that cocoa but not tea is linked to blood pressure reduction. The study is published in the American Medical Association journal Archives of Internal Medicine...[read article]

Biomedical Pain-source Detector Seen As Potentially Revolutionary

Preliminary Payments To Companies Providing Medicare Advantage Plans Will Increase By 3.5% In 2008, CMS Says

Benefits Of Good Doctor-patient Communication - Outcomes Improve

HRT Does Not Increase Heart Attack Risk Among Women In Their 50s, New WHI Analysis Finds

Study Of Twins Shows That Altruistic Behavior Not Strictly Environmental

7 Common Myths About Irritable Bowel Syndrome

Hope For Ending The Pain, Infertility Of Endometriosis?

Hot Flashes In Women Linked To High Blood Pressure

Frequent Infections May Be A Sign Of Immunodeficiency

Almac Announces New Research On Colorectal Pre Malignancies

Health Affairs Web Exclusive Examines Physician Use Of E-Prescribing

New Rhode Island Rules Require Hospitals To Provide No-Cost Care To Low-Income Residents

Genes Found For Successful Smoking Cessation

U.S. Health Care System Should Focus On Preventive Health, According To Report

SUSAN SWARTZ: Judges send mixed smoke signals

You have to wonder what the judges were smoking. I’m referring to the federal court of appeals that ruled a sick mother of two from Oakland cannot use medical marijuana.Even though what she’s doing is legal under California law and even though her doctors say smoking marijuana is the only thing that motivates her to eat and deal with the pain from scoliosis, a brain tumor and endometriosis, the court says Angel Raich is a criminal in the eyes of the federal government.The government stands firm that marijuana is an illegal controlled substance with no medical value. The federal government doesn’t buy the argument that gravely ill people have the right to use marijuana when legal drugs fail.The government says there’s no scientific proof that ingesting or inhaling marijuana makes a difference to sick people. This is, of course, the same government that picks and chooses the scientific arguments it likes -- global warming being highly exaggerated and stem-cell research a plot to kill babies.This federal government would tell sick people to just pray and take a pill. This government believes if teenagers and other suggestible Americans ever saw Raich using marijuana, they, too, might want to acquire scoliosis, a brain tumor and endometriosis so they could get high and eat brownies.Meanwhile, the tobacco industry has been out looking for young women to sicken.There’s no lack of scientific proof that smoking tobacco can lead to lung cancer, heart disease, stroke, emphysema and other miseries. But it’s still legal to grow and sell the stuff, even though finding a legal place to puff is becoming harder all the time.Because the tobacco industry is being squeezed -- not unlike the way someone with scoliosis, emphysema and a brain tumor must feel every day of her life -- the R.J. Reynolds Tobacco Co. has come up with a new cigarette for women called Camel No. 9.Clever marketing makes Camel No. 9 sound more like a fashion accessory than a cancer stick. The name suggests a connection to the perfume Chanel No. 9 or the song “Love Potion No. 9." The cigarettes, which come in a sexy package of basic black with fuchsia touches, is being advertised in fashion magazines and promoted at “Girls Night Out" events at nightclubs, though the Camel people insist no one under 21 is allowed in their parties.The tobacco industry has been hit hard by a drop in female smokers in recent years. Maybe women finally got the message that lung cancer kills more women than breast cancer. Or maybe they realized that those little smoking lines you get around your mouth never disappear.So of course there’s a desperate push to win the girls back. In a business story on the new cigarette, Wall Street analysts praised R.J. Reynolds for its successful marketing strategy.Now a British study has come out with a list of the most dangerous substances. Heroin is first. Tobacco is ninth. Marijuana is 11th.I wonder how many people who are dying because they or someone close to them smoked tobacco now use marijuana to lessen their pain. They, if no one else, see the absurdity of a society where pushing a drug that kills is business but using a drug that helps you live is a crime.Susan Swartz is a columnist for The Press Democrat in Santa Rosa, Calif.
Source

Adhesions Medical Headlines ARDvark Blog

A Simple New Way To Predict Advanced Fibrosis In Patients With Nonalcoholic Fatty Liver Disease

Breakthrough MS Treatment Doesn't Reach US Patients

Spotting Cervical Cancer Quicker In Developing Countries

Hemorrhoids Relief & Treatment

Hemorrhoids Prevention And Causes

Biofeedback Treats One Type Of Chronic Constipation

Disabled Hit Huge Roadblocks In Routine Health Care

Few Private Insurance Plans Provide Brand-Name Prescription Drug Coverage During Medicare 'Doughnut Hole'

Trust Us, We're Doctors - Image Of Professions Survey, Australia

Hospital Errors Rise 3 Percent -- HealthGrades Patient-safety Study

Callisto Intends To Move Guanilib Into Clinical Trials In Ulcerative Colitis

Monthly Premiums For Low-Cost Health Plans In Massachusetts Fell By 8% In Second Round Of Bidding

NEJM Perspective Analyzes Bush's Tax-Based Health Care Proposals

New Study In SLEEP Finds That Sleep Disturbance Increases Spontaneous Pain In Women

Controlling C Difficile In The Community Could Cut Infection Rates In Hospitals

FDA Announces Discontinued Marketing Of GI Drug, Zelnorm, For Safety Reasons, USA

Harvard And U. Pittsburgh Researchers Explain Carbon Monoxide's Anti-inflammatory Effects

Reuters Examines Obstetric Fistula, Impact On Women

Women Are Unaware of the Dangers of Surgical Adhesions

Women focus on short-term concerns prior to pelvic surgery, not lasting complications.Although more than half of the country's women will have some type of pelvic surgery and are therefore at risk for surgical adhesions, a survey released this month by the not-for- profit National Women's Health Resource Center (NWHRC) finds that women are largely unaware of the health risks associated with adhesions.Surgical adhesions occur when tissue in the abdominal cavity adheres, or gets stuck to other tissue. Adhesions commonly form following pelvic surgeries, such as hysterectomy, tubal ligation, cesarean section, and cyst removal. Left untreated, adhesions can cause infertility, abdominal pain, and bowel obstruction.The survey of 1,000 women showed respondents strongly believe women should be informed about surgical adhesions prior to surgery (69%). Conversely, an overwhelming majority of women (80%) who had pelvic surgery were not informed about adhesions prior to their surgery. Of the women in the survey who suffer from adhesions, seven out of ten (70%) say they would have taken special precautions to protect themselves from getting adhesions if they had been aware of possible adhesion-related complications.

Susan Jones, a human resources director and mother of three from McLean, Virginia, has experience with the long-term effects adhesions can have on a person's health. All of Jones's children were delivered by cesarean section. Due to adhesions caused by these three surgeries, she suffers from reoccurring abdominal pain and has been advised not to have any more children because of the increased difficulty of delivering a baby surrounded by such a large amount of scar tissue."My first c-section only took about 10 minutes for the doctor to get the baby out," said Jones. "My second c-section took nearly 45 minutes and my final c-section took nearly an hour and a half. My doctor had such a hard time maneuvering around the scar tissue to get to my baby.""If I had known about adhesions," continued Jones, "I would have talked to my doctor about what can be done to reduce my risk for getting them."Like Ms. Jones, half (51%) of survey respondents were not aware that preventative measures can be taken to lower your risk of adhesions and an even higher proportion (68%) of women that had undergone surgery did not know if their surgeon took specific steps to guard against adhesions. Read More
http://www.emaxhealth.com/4/10787.html

Atrium Medical Receives FDA Approval for its Novel C-QURLite(TM) Mesh

HUDSON, N.H., April 9 /PRNewswire/ -- Atrium Medical Corporation ispleased to announce it has obtained US FDA 510(K) approval for a new Omega3 surgical mesh product called C-QURLite(TM) Mesh. This new product is indicated for use in the surgical repair andreinforcement of soft tissue, including hernia repair -- a common procedureperformed more than 700,000 times in the US each year. This noveltechnology combines Atrium's ProLite Ultra(TM) polypropylene surgical meshwith a proprietary, pharmaceutical grade Omega 3 fatty acid bio-absorbablegel coating. Unlike traditional tissue separating mesh products, C-QURLiteMesh enhances the handling stiffness and healing response in pre-peritonealplacement when compared to other "bare" polymer mesh products currentlyused for hernia repair. C-QURLite Mesh is constructed from the refined ProLite Ultrapolypropylene monofilament, providing a low profile, strong, lightweightbase structure. The novel all natural Omega 3 gel coating is then appliedin a proprietary method, coating each monofilament of the mesh to enhancematerial handling and subsequent healing. This non-polymeric,bio-absorbable coating has demonstrated in pre-clinical studies tosignificantly improve anatomical conformance by reducing aggressive, denseacellular collagen formation known to induce adhesions following surgery. Atrium's discovery of combining inert thin wall polypropylene mesh withan Omega 3 biological coating in pre-clinical studies has demonstratedminimization of peritoneal tissue attachment as well as a significantreduction in both foreign body reaction and inflammation, resulting in awell healed, reinforced soft tissue repair. The novel C-QURLite Mesh BAOcoating (BioAbsorbable Oil) also enhances ease of handling and tissue planeplacement, which subsequently forms into an elegant soft and flexibleimplant. It offers improved stiffness and handling qualities preferred bymany of today's discriminating surgeons while maintaining excellentsee-thru visibility to underlying tissue landmarks for improved anatomicalorientation during surgical installation. The use of Atrium's all natural Omega 3 bio-absorbable coating with itsadvanced lightweight surgical mesh provides today's clinicians with a broadspectrum of options for both laparoscopic and open surgical repair. Thisfirst to market BAO coating technology enables cells to freely grow throughthe porous mesh implant during healing immediately following soft tissuerepair. Atrium's C-QURLite Mesh will be available in a wide variety ofpreferred anatomical laser cut shapes and sizes mid-year 2007. About Atrium Atrium's vast expertise in medical device technologies for thetreatment of cardiovascular disease, hernia and adhesion prevention hasbrought a number of breakthrough advances in several diversified healthcaremarkets including interventional cardiology and radiology, chest traumacare and thoracic drainage, vascular surgery, and soft tissue repair.Maintaining a commitment to the latest ISO13485 Quality Standards,state-of-the-art manufacturing and automation, cell biology and biomaterialdiscovery programs, Atrium continues to excel in those healthcare segmentsthat require more advanced surgical intervention for improvements inpatient outcome. For more information call 800-370-7899 or visit Atrium'swebsite http://www.atriummed.com.

SOURCE Atrium Medical Corporation

Adept (icodextrin 4% solution) reduces adhesions after laparoscopic surgery for adhesiolysis: a double-blind, randomized, controlled study.

Brown CB,
Luciano AA,
Martin D,
Peers E,
Scrimgeour A,
Dizerega GS;
on behalf of the Adept Adhesion Reduction Study Group.
University of Sheffield, Sheffield, United Kingdom.
OBJECTIVE: To evaluate the efficacy and safety of Adept (4% icodextrin solution) in reducing adhesions after laparoscopic gynecological surgery involving adhesiolysis. DESIGN: Multicenter, prospective, randomized, double-blind study comparing Adept with lactated Ringer's solution (LRS). PATIENT(S): Four hundred two patients randomized intraoperatively to Adept (n = 203) or LRS (n = 199) returned for second laparoscopy within 4-8 weeks. Incidence, severity, and extent of adhesions were determined on both occasions. MAIN OUTCOME MEASURE(S): The primary efficacy measure defined by the Food and Drug Administration was the number of patients achieving clinical success with adhesion treatment. Other measures included incidence and American Fertility Society (AFS) scores. RESULT(S): Significantly more Adept patients achieved clinical success than did LRS patients (49% vs. 38%). In infertility patients, Adept demonstrated particular clinical success compared with LRS (55% vs. 33%). This was reflected in the number of patients with a reduced AFS score (53% vs. 30%) and in fewer patients with a moderate/severe AFS category score (43% vs. 14%). Safety was comparable in both groups. Most events were related to the surgery, with an increase in transient labial edema in the Adept group. CONCLUSION(S): This is the first randomized, double-blind trial of an adhesion reduction agent. It demonstrated that Adept is a safe and effective adhesion reduction agent in laparoscopy.
PMID: 17383643 [PubMed - as supplied by publisher]
Source

Adhesions Medical Headlines ARDvark Blog

Delayed Hormone Therapy Could Increase Heart Disease Risk
Written by Catharine Paddock
A new US study suggests that the risk of heart disease for postmenopausal women taking hormone therapy could go up the longer she leaves it after starting menopause...[read article]

New Analysis Of Data From WHI Provides Reassurance With Respect To Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy

Ibuprofen May Boost Chance Of Heart Problems In High Risk Patients With Osteoarthritis

Stereotaxis Announces FDA Approval Of Partnered 8mm Ablation Catheter

New 'Targeted' Treatments Improve Colon Cancer Survival Rates

HHS Inspector General Office To Review Conflicts Of Interest For NIH Grantees, Employees

Penn Study Points To New Direction For Pancreas Cell Regeneration - Implications For Diabetes, Other Pancreatic Disorders

Winkie Pratney, Well-Known Minister to Young People Around the World, in Serious Condition in South Korean Hospital

Le 3 avril 2007, par Aloys Evina,
By Michael Ireland
SOUTH KOREA — Winkie Pratney, who logs more than 150,000 miles in his quest to speak to half-a-million young people each year, is in critical medical condition in a hospital in South Korea. He is currently in septic shock, which is life-threatening.
Winkie fell last week in S. Korea, which led to surgery and a series of complications, according to a blog on his website www.winkiepratney.com.
« His first surgery (a herniotomy) was on March 26. The next day it was clear that there were more problems than just than a hernia, so Winkie underwent major surgery on his whole abdominal cavity. They found several adhesions of his bowel which were causing intestinal obstruction, » says Steve Loopstra, executive director of the Minneapolis, Minnesota-based Prayer Transformation Ministries, in a prayer update.
Loopstra says : "The condition of his transverse colon was very severe, so they performed a segmental resection where portions of his colon were removed entirely. In addition to this, he suffered micro-ruptures at certain points that were repaired.
« Winkie began to improve and talked with his wife, who has now flown in from Australia. But in the past day, his condition has worsened and he is now in septic shock, with his vital organs failing. »
Loopstra commented : « Winkie is a hero of faith, having ministered to the lives of countless thousands of people, especially young adults. He is a brilliant teacher and a gift to the nations. Please be in prayer for Winkie and his family at this critical time. »
Pratney’s website profile says that Winkie has wide experience in youth work.
"His technical background in both science and the popular music culture has given him a unique insight to the particular needs of a media-dominated technological society, and his constant monitoring of youth trends combined with continual feedback from young people themselves has helped him interpret these for those with a vital interest in the welfare of the young.
« Besides annual leadership training seminars he has for three decades helped challenge and inspire young people to holy and happy living. Winkie is involved with helping and training young people of all ages and works with many leading international youth movements including Campus Life, Champions For Christ, Operation Mobilization, Masters Commission, Youth With A Mission, Young Life, Youth Alive, and Teen Challenge. He conducts yearly leadership training for youth workers in Europe, North America and the Pacific, and has been involved as an advisory and consultant to church, civic, educational, government and social welfare leaders on the needs and problems of modern teenagers. He occasionally speaks in churches, but his primary call is to students. »
The site says that as a frequent featured speaker and guest on national television talk shows, his audio and video-tape lectures are carried by many effective outreach ministries as part of their training.
"Winkie has authored more than twelve books including youth manuals like the best-selling Youth Aflame !, Handbook For Followers Of Jesus, books on contemporary and historical issues like Devil Take The Youngest, Revival - Twenty Centuries Of Vision and Visitation, Dealing With Doubt and evangelistic and apologetic works like the contemporary devotional theology The Nature And Character Of God.
Read More

Twin gets kidney

Transplant goes smoothly from mom to Maliyah
By Lois M. CollinsDeseret Morning News
Maliyah Herrin, 5, is in critical condition at Primary Children's Medical Center after receiving her mother's right kidney in an operation that took nearly seven hours Tuesday. Erin, her mother, is in fair condition.
The surgery team cheered when Erin Herrin's kidney changed ownership and started producing urine just minutes after it was implanted in the little girl's abdomen.
"It's always exciting to see a kidney that has been taken from one individual basically come alive in another individual," said transplant surgeon Dr. John Sorensen. "I never get tired of it." Maliyah and her twin sister, Kendra, were born joined at the abdomen. They shared several organs and a pelvis, as well as use of Kendra's kidney until they were surgically separated in August. The decision on when to separate them and much of the reconstruction done during that operation were driven by knowledge that Maliyah would need a kidney transplant afterward. She has since been on dialysis three days a week.
"Looking back, it's amazing how far we've come. We thought we'd never get to this point. We're really through the big challenges," said Jake Herrin after the transplant, which is expected to be the last major childhood surgery for either twin.
The entire transplant took nearly seven hours and was much less complex than doctors had feared it would be. There were no complications, said Sorensen and Dr. Rebecka Meyers, who was on Maliyah's transplant team and who was coordinating surgeon during the 26-hour separation surgery last summer.
When the surgery transferring the kidney from his wife to his daughter was over, Jake Herrin thanked the surgical teams repeatedly for what he called "miracle after miracle."
Monday, Maliyah had been excited and "bouncing off the walls" happy after her final dialysis session, Jake said. She told everyone she met she was getting a new kidney tomorrow.
She had a good night's sleep Monday and was groggy and tired when it was time to go to surgery. She didn't fuss, although she clouded up briefly as she was taken from her parents. She was calm as child life specialist Holly Moss-Rosen carried her into the operating room at 7:46 a.m., where a staffer read "Madeleine" to her until the anesthesia put her to sleep. Doctors spent the next hour assessing what to do and examining images before making the first incision. They feared they would find a lot of scar tissue and adhesions from the extensive separation surgery but were "pleasantly surprised," said Meyers, who said the less-than-expected scarring indicates Maliyah heals well.
The bladder reconstruction that urologist Dr. Patrick Cartwright did in August to prepare for a kidney transplant had held up well, too. And Dr. Eric Scaife, a transplant surgeon who was part of the team working on Erin, said the donor kidney was healthy and had a single artery and a single vein, which makes implantation much simpler. Everything went smoothly removing the kidney from Erin, "with zero blood loss."
Surgeons had also worried that space in Maliyah's abdomen would be a problem, since the two girls had shared one abdomen only slightly larger than that of a normal child. Although it was tight, it was adequate, helped in part by the fact that the kidney Erin donated was slightly small for an adult kidney.
The surgical team for Maliyah included two transplant surgeons, a urologist, a plastic surgeon and an anesthesiologist. Erin's team included two transplant surgeons and an anesthesiologist. Each team also had a registered nurse and an operating room tech, and another of each helped as needed.
Read More

Adhesions Medical Headlines ARDvark Blog

3M Health Care Launches A New Weapon In The Fight Against MRSA - The First Rapid Culture-based Test With Results In Five Hours

The Gap Between Results From Controlled Trials And Results In The Real World, From The 'Harvard Mental Health Letter'

EndoGastric Solutions Receives FDA Clearance For First Transoral Surgical Product: StomaphyX(TM) Gets Clearance First

Boston IVF Egg Freezing Study Results In Pregnancy

Using Simulators To Practice High-risk Resuscitations

Magnetic System Could Be Key To Surgery Without Scars

Physicians at UT Southwestern Medical Center and engineers at UT Arlington have collaborated to invent a groundbreaking system that could be key to delivering on the promise of surgery without scars. The new technique, which is still in the developmental stage, allows for magnetically maneuvering laparoscopic surgical tools inserted into the abdominal cavity through the bellybutton or throat. The challenge remains, however, to design the new instruments and determine just how to move them once they're inside the human body. "A fixed hole has a limited working envelope that is conical in shape," said Dr. Jeffrey Cadeddu, associate professor of urology and radiology and director of the Clinical Center for Minimally Invasive Treatment of Urologic Cancer. He and his colleagues describe the new surgical concept, called the Magnetic Anchoring and Guidance System, in the March edition of Annals of Surgery. The idea of using magnets to manipulate the instruments in the abdominal cavity was formulated after Dr. Cadeddu watched a television show featuring teens who used magnets to hold studs on their lips to avoid getting their lips pierced. "Once you think about, it's an obvious thing," said Dr. Cadeddu, whose team of urologists and surgeons worked with engineers from UTA's Automation and Robotics Research Institute and the Texas Manufacturing Assistance Center to build the prototype. The system uses a stack of magnets outside the abdomen to attract other magnets attached to laparoscopic instruments inside the abdomen. Surgeons can then move the outside magnets to position an internal camera at the best spot for seeing or to move a retractor or other surgical instrument. Once optimally positioned, the instruments can be locked in place. That allows a much greater range of maneuverability and the surgical team can more easily reposition the camera or instrument, said Dr. Cadeddu. In animal studies, surgeons have been able to successfully remove a kidney using the Magnetic Anchoring and Guidance System. While working on the system, Dr. Daniel Scott, assistant professor of surgery, joined UT Southwestern as director of the Southwestern Center for Minimally Invasive Surgery. He said the technology may solve the fundamental problem of guiding instruments through the abdomen for natural orifice surgery, which now inserts the instruments through the throat, colon or vagina. "The current state of the art for laparoscopic surgery requires four or five holes. The question behind this is, can we do the surgery through only one hole and can we hide the hole in a cosmetically advantageous or less painful location," Dr. Cadeddu said. Study researchers concluded that "the ability to reduce the number of trocars (holes) necessary for laparoscopic surgery has the potential to revolutionize surgical practice," but noted that there will be a learning curve for the new system and that because of the expanded maneuverability, surgeons will likely need to develop new techniques. Also, until the system is fully tested in humans, surgeons won't know whether fewer entry points will result in fewer complications or faster healing, advantages usually seen in moving from conventional surgery to laparoscopic surgery. ### Other UT Southwestern researchers involved in the paper were Dr. Sangtae Park, a former assistant instructor; Dr. Robert Eberhart, adjunct professor of surgery; and Dr. Linda Baker, associate professor of urology. About UT Southwestern Medical Center UT Southwestern Medical Center, one of the premier medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. Its nearly 1,500 full-time faculty members - including four active Nobel Prize winners, more than any other medical school in the world - are responsible for groundbreaking medical advances and are committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to about 92,000 hospitalized patients and oversee 1.7 million outpatient visits a year.
This news release is available on our World Wide Web home page at http://www8.utsouthwestern.edu/utsw/cda/dept37389/files/348531.html
To automatically receive news releases from UT Southwestern via e-mail, subscribe at http://www.utsouthwestern.edu/receivenews
Dr. Jeffrey Cadeddu - http://www.utsouthwestern.edu/findfac/professional/0,2356,41601,00.html
Contact: Russell RianUT Southwestern Medical Center

Source

Kidney transplant scheduled Tuesday for Herrin twin

Kidney transplant scheduled Tuesday for Herrin twin
By Lois M. CollinsDeseret Morning News
Maliyah Herrin will receive one of her mother's kidneys Tuesday in what is hoped will be the last major childhood surgery for the formerly conjoined twin.
Maliyah and her twin sister Kendra, 5, daughters of Jake and Erin Herrin of North Salt Lake, were born joined at the abdomen. They were separated in a 26-hour marathon surgery last August. Maliyah has undergone dialysis three times a week since that operation because the two girls had shared Kendra's kidney.
Monday morning, as mother and daughter were undergoing final tests prior to the transplant, an excited Maliyah told Primary Children's Medical Center spokeswomen Bonnie Midget, "I get my kidney tomorrow." S
he's not particularly looking forward to an operation, but "she definitely wants a kidney," said Dr. John Sorensen, one of the transplant surgeons, who added that she has "incredible insight into what's happening."
When two large surgical teams separated the twins Aug. 7, many of the decisions they made in reconstructing Maliyah's abdomen had the future kidney transplant in mind. For instance, Dr. Patrick Cartwright, a pediatric urologist, formed her bladder with an eye to the future transplant. He's part of Tuesday's surgical team, as well.

An expandable "spacer" device was also implanted in Maliyah's abdomen to make room for the kidney that would be implanted, said Dr. Rebecka Meyers, who led the separation-surgery teams and will be one of the kidney transplant surgeons. The adult-sized kidney will have to be placed so it doesn't put pressure on organs or blood vessels.
It is more common for children to receive an adult-sized kidney than to receive a child-sized one, Sorensen said.
Still, it will not be a routine transplant surgery, since Maliyah's anatomy is different. The twins shared an abdomen and each had control of one of their legs. After separation, the surgeons had to build each girl a partial abdominal wall. There are other abnormalities as well, including unusual blood vessel anatomy and differences in Maliyah's urinary system. The surgeons will also face scar tissue and adhesions from the separation surgery, which is likely to extend the transplant time to as long as eight hours, rather than the more typical two or three hours, which is about how long Erin Herrin's surgery is expected to take.
Sorensen said the complexity of the surgery will increase the physiological demands on Maliyah's body.
"We don't necessarily have to create structures that don't exist, but we have to work within the confines of her structure," Sorensen said.
Read More

Adhesions Medical Headlines ARDvark Blog

Leading Experts Call For Immediate Improvements To Control Global Hospital Infection Epidemic Of Clostridium-Difficile-Associated Disease

Managing Your Moods Can Benefit Your Health

Gene Behind Autoimmune Diseases Identified By Researchers

Black Raspberries May Slow Growth Of Colon, Other Cancers

Thinks Herbal Supplements Are Safe? Think Again, Suggests Doctor

Where's Your Pain? New Insights Into How The Brain Processes Pain Location

Omega-3 Fatty Acids Affect Risk Of Depression, Inflammation

European Union CHMP Recommends Approval Of First And Only Biologic Treatment For Pediatric Crohn's Disease: REMICADE®

Novel Anti-oxidant And Anti-inflammatory Agent Shows Effectiveness On Key Endpoints In Trial

MiraLax Switches From Prescription To Over-the-counter Status

New Strain May Make A Common Bacterial Illness More Severe, Reports The 'Harvard Women's Health Watch'

World's First 'Smart' Robotic Micro-drill Used In Surgical Operation

Surgeons Sharpen Skills With New Training Simulator

Polymers Show Promise For Gene Delivery, Tissue Scaffolds, Other Biomedical Applications

New Insights Into How The Brain Processes Pain Location

Tequila Raw Ingredient Being Developed Into Drug-carrier That Targets Colon Diseases

Get In Swing Without Tendon Pain

Kidney Failure Can Result From Iodine Dye Used For X-Rays Data Shows

Pharmacies Fighting President Bush Proposal To Reduce Reimbursements For Generic Prescription Drugs Under Medicaid

Pain Control After Surgery Reduces Days Of Hospitalization

Oxygen-concentrating Wound Dressing Delivers A Breath Of Fresh Air To Hard-to Heal Wounds

Supermarket Surgeries 'a Wake-up Call For The Profession', UK

Blueberries Contain Chemical That May Help Prevent Colon Cancer

Sen. Clinton Vows To Establish Universal Health Care System If Elected President In 2008

MUSC Research Offers Hope For Those Resistant To Depression Treatment

Nuvelo Receives FDA Fast Track Status For RNAPc2 In Both First- And Second-Line Treatment Of Metastatic Colorectal Cancer

Study Describes Action Of Estrogen In Protecting Bone

Dispelling The Top 10 Nutrition Myths

Unacceptable Variation In Care For People With Inflammatory Bowel Disease - Royal College Of Physicians Of London